Atrium Therapeutics, Inc. Common Stock Total Liabilities
Atrium Therapeutics, Inc. Common Stock total liabilities. Based on the latest financial reports, Atrium Therapeutics, Inc. Common Stock (RNA) has total liabilities worth $71.07 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Atrium Therapeutics, Inc. Common Stock (RNA) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Atrium Therapeutics, Inc. Common Stock (2011–2025)
Total liabilities of Atrium Therapeutics, Inc. Common Stock from 2011 to 2025. This chart illustrates how Atrium Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
Atrium Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Atrium Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Suheung Capsul
KO:008490
|
Korea | ₩520.12 Billion |
|
Basso Industry Corp
TW:1527
|
Taiwan | NT$625.95 Million |
|
YESASIA HOLDINGS LTD
F:4CM
|
Germany | €83.70 Million |
|
Nynomic AG
F:M7U
|
Germany | €32.87 Million |
|
Manulife Holdings Bhd
KLSE:1058
|
Malaysia | RM6.83 Billion |
|
Sajo Ind
KO:007160
|
Korea | ₩617.05 Billion |
|
Heungkuk F&M I
KO:000540
|
Korea | ₩12.24 Trillion |
|
MEDIFAST INC
NYSE:MED
|
USA | $64.02 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Atrium Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Atrium Therapeutics, Inc. Common Stock total assets.
Liquidity & Leverage Metrics
Atrium Therapeutics, Inc. Common Stock Total Liabilities Ratios Explained
Atrium Therapeutics, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Atrium Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Atrium Therapeutics, Inc. Common Stock (2011–2025)
The table below shows the annual total liabilities of Atrium Therapeutics, Inc. Common Stock from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $71.07 Million | -48.85% |
| 2024-12-31 | $138.94 Million | +8.72% |
| 2023-12-31 | $127.79 Million | +110.44% |
| 2022-12-31 | $60.73 Million | +31.58% |
| 2021-12-31 | $46.15 Million | +66.76% |
| 2020-12-31 | $27.68 Million | -82.94% |
| 2019-12-31 | $162.26 Million | +259.70% |
| 2018-12-31 | $45.11 Million | +18.70% |
| 2013-12-31 | $38.00 Million | -9.24% |
| 2012-12-31 | $41.87 Million | +43.06% |
| 2011-12-31 | $29.27 Million | -- |
About Atrium Therapeutics, Inc. Common Stock
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treat… Read more